All PlansCoverageMedium impact
Genetic Testing for Developmental Delay/Intellectual Disability, Autism Spectrum Disorder, and Congenital Anomalies
Blue Cross & Blue Shield of Mississippi·MS · Pediatrics, Neurology, Family Medicine·Medical Policy
We identified it
Jun 20, 2026
Summary
This policy establishes coverage guidelines for genetic testing including chromosomal microarray (CMA) and next-generation sequencing for children with developmental delay, intellectual disability, autism spectrum disorder, and congenital anomalies. The policy outlines when these advanced genetic tests are appropriate and covered.
Action Required
Billing team should review current genetic testing claims to ensure they align with the new coverage criteria for CMA and next-generation sequencing tests. Verify that documentation supports medical necessity for developmental delay, intellectual disability, autism spectrum disorder, or congenital anomalies before submitting claims for genetic testing services.